Review
doi: 10.1007/s11934-004-0050-6.
The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data
Affiliations
- PMID: 15260927
- DOI: 10.1007/s11934-004-0050-6
Item in Clipboard
Review
The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data
Curr Urol Rep.
2004 Aug.
Abstract
Medical treatment for the symptoms of benign prostatic hyperplasia (BPH) consists of a blockers and 5-alpha-reductase inhibitors. Data suggest that 5-alpha-reductase inhibitors can prevent progression of BPH and reduce the risk of BPH-related surgery, especially in men with large-volume prostates. Results from the largest randomized, prospective, placebo-controlled trial, the Medical Therapy of Prostatic Symptoms trial, have been presented. These results support the notion of using 5-alpha-reductase inhibitors for the prevention of BPH progression and BPH-related surgery. Furthermore, long-term 5-alpha-reductase inhibitor monotherapy, although slow in onset, is a viable therapy for symptom relief in men with mild to moderate symptoms.
Similar articles
-
Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.Am J Geriatr Pharmacother. 2005 Jun;3(2):103-14. doi: 10.1016/s1543-5946(05)00031-0. Am J Geriatr Pharmacother. 2005. PMID: 16129387 Review.
-
Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.World J Urol. 2002 Apr;19(6):413-25. doi: 10.1007/s00345-002-0248-5. World J Urol. 2002. PMID: 12022710 Review.
-
Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.Contemp Clin Trials. 2007 Nov;28(6):770-9. doi: 10.1016/j.cct.2007.07.008. Epub 2007 Aug 2. Contemp Clin Trials. 2007. PMID: 17761460 Clinical Trial.
-
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.Eur Urol. 2010 Jan;57(1):123-31. doi: 10.1016/j.eururo.2009.09.035. Epub 2009 Sep 19. Eur Urol. 2010. PMID: 19825505 Clinical Trial.
-
Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.Arch Ital Urol Androl. 2009 Mar;81(1):1-8. Arch Ital Urol Androl. 2009. PMID: 19499750 Review.
Cited by
-
Management of urinary incontinence.P T. 2012 Jun;37(6):345-361H. P T. 2012. PMID: 22876096 Free PMC article. No abstract available.
-
In vitro effect of D-004, a lipid extract of the fruit of the cuban royal palm (Roystonea regia), on prostate steroid 5α-reductase activity.Curr Ther Res Clin Exp. 2006 Nov;67(6):396-405. doi: 10.1016/j.curtheres.2006.12.004. Curr Ther Res Clin Exp. 2006. PMID: 24678112 Free PMC article.
-
Plasma levels, tissue distribution, and excretion of radioactivity after single-dose administration of ((3)H)-oleic acid added to D-004, a lipid extract of the fruit of Roystonea regia, in rats.Curr Ther Res Clin Exp. 2006 Nov;67(6):406-19. doi: 10.1016/j.curtheres.2006.12.005. Curr Ther Res Clin Exp. 2006. PMID: 24678113 Free PMC article.
-
Effects of D-004, a lipid extract from Cuban royal palm fruit, on inhibiting prostatic hypertrophy induced with testosterone or dihydrotestosterone in a rat model: A randomized, controlled study.Curr Ther Res Clin Exp. 2004 Nov;65(6):505-14. doi: 10.1016/j.curtheres.2005.01.001. Curr Ther Res Clin Exp. 2004. PMID: 24672102 Free PMC article.
-
Effects of D-004, a lipid extract of the fruit of the Cuban royal palm (Roystonea regia) or the lipidosterolic extract of saw palmetto (Serenoa repens) on the sexual activity in male rats: A controlled, experimental study.Curr Ther Res Clin Exp. 2008 Feb;69(1):65-74. doi: 10.1016/j.curtheres.2008.01.002. Curr Ther Res Clin Exp. 2008. PMID: 24692784 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical